Colorectal Cancer

General Cancer

Axel Grothey, MD, discusses the results from the safety lead-in phase of the BEACON CRC trial investigating the triplet regimen of BRAF inhibitor encorafenib, MEK inhibitor binimetinib, and anti-EGFR antibody cetuximab in&nbsp;patients with&nbsp;<em>BRAF</em>V600E-mutant metastatic colorectal cancer.

A&nbsp;direct-to-consumer genetic test has been approved by the FDA for providing a&nbsp;risk report on MUTYH-associated polyposis, a hereditary colorectal cancer syndrome, according to&nbsp;23andMe, the personal genetics company that manufactures the test.<br /> &nbsp;

Michael J. Overman, MD, discusses the data presented at the 2019 Gastrointestinal Cancers Symposium for the phase II CheckMate-142 in previously treated patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer.

Treatment with&nbsp;durvalumab demonstrated&nbsp;objective responses in approximately one-fourth of patients with&nbsp;microsatellite instability-high advanced solid tumors, including colorectal cancer, according to data from 2 preliminary clinical trials.

When&nbsp;durvalumab and tremelimumab were combined with&nbsp;best supportive care, the combination reduced the risk of progression or death by 28% compared with best supportive care alone, according to findings from a phase II clinical trial.&nbsp;

Updated findings from the&nbsp;safety lead-in phase of the BEACON CRC trial showed an estimated survival time beyond historic controls from treatment with a triplet combination of&nbsp;encorafenib, binimetinib, and cetuximab for patients with&nbsp;<em>BRAF&nbsp;</em>V600E-mutant metastatic colorectal cancer.&nbsp;

Pashtoon M. Kasi, MD, MBBS, MS, discusses how the triplet regimen of the BRAF inhibitor encorafenib, the MEK inhibitor binimetinib, and the EGFR inhibitor cetuximab, will impact the treatment landscape for patients with metastatic colorectal cancer.

Pashtoon M. Kasi, MD, MBBS, MS,&nbsp;discusses recent advances with individualized medicine in CRC, as well as the unmet needs that still exist in this area.

Due to the significant decline in smoking and an increase in advances for early cancer detection and screening, the cancer death rate has declined 27% in the United States from 1991 to 2016, according to the American Cancer Society&rsquo;s annual report on cancer rates.

Al B. Benson III, MD, FACP, FASCO, professor of medicine at Northwestern University, shares advice to community oncologists treating patients with colorectal cancer. He emphasizes looking carefully at different patient characteristics before making treatment decisions.

The first patient has been enrolled in the pivotal phase III AGENT trial, which is investigating arfolitixorin in combination with 5-fluorouracil, oxaliplatin, and bevacizumab compared with FOLFOX plus bevacizumab in patients with metastatic colorectal cancer, according to Isofol Medical AB, the company developing arfolitixorin.